ZA911553B - Tri-and tetra-substituted guanidines and their use as excitatory amino acid and antagonists - Google Patents

Tri-and tetra-substituted guanidines and their use as excitatory amino acid and antagonists

Info

Publication number
ZA911553B
ZA911553B ZA911553A ZA911553A ZA911553B ZA 911553 B ZA911553 B ZA 911553B ZA 911553 A ZA911553 A ZA 911553A ZA 911553 A ZA911553 A ZA 911553A ZA 911553 B ZA911553 B ZA 911553B
Authority
ZA
South Africa
Prior art keywords
disease
brain
tetra
tri
substituted guanidines
Prior art date
Application number
ZA911553A
Other languages
English (en)
Inventor
Eckard Weber
Weber Eckard
John F W Keana
F W Keana John
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Publication of ZA911553B publication Critical patent/ZA911553B/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/435—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by selective application of radiation to a printing material or impression-transfer material
    • B41J2/47—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by selective application of radiation to a printing material or impression-transfer material using the combination of scanning and modulation of light
    • B41J2/471—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by selective application of radiation to a printing material or impression-transfer material using the combination of scanning and modulation of light using dot sequential main scanning by means of a light deflector, e.g. a rotating polygonal mirror
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03G—ELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
    • G03G15/00—Apparatus for electrographic processes using a charge pattern
    • G03G15/14—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base
    • G03G15/16—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base of a toner pattern, e.g. a powder pattern, e.g. magnetic transfer
    • G03G15/1665—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base of a toner pattern, e.g. a powder pattern, e.g. magnetic transfer by introducing the second base in the nip formed by the recording member and at least one transfer member, e.g. in combination with bias or heat
    • G03G15/167—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base of a toner pattern, e.g. a powder pattern, e.g. magnetic transfer by introducing the second base in the nip formed by the recording member and at least one transfer member, e.g. in combination with bias or heat at least one of the recording member or the transfer member being rotatable during the transfer
    • G03G15/1675—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base of a toner pattern, e.g. a powder pattern, e.g. magnetic transfer by introducing the second base in the nip formed by the recording member and at least one transfer member, e.g. in combination with bias or heat at least one of the recording member or the transfer member being rotatable during the transfer with means for controlling the bias applied in the transfer nip
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03G—ELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
    • G03G15/00—Apparatus for electrographic processes using a charge pattern
    • G03G15/14—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base
    • G03G15/16—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base of a toner pattern, e.g. a powder pattern, e.g. magnetic transfer
    • G03G15/1665—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base of a toner pattern, e.g. a powder pattern, e.g. magnetic transfer by introducing the second base in the nip formed by the recording member and at least one transfer member, e.g. in combination with bias or heat
    • G03G15/167—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base of a toner pattern, e.g. a powder pattern, e.g. magnetic transfer by introducing the second base in the nip formed by the recording member and at least one transfer member, e.g. in combination with bias or heat at least one of the recording member or the transfer member being rotatable during the transfer
    • G03G15/168—Apparatus for electrographic processes using a charge pattern for transferring a pattern to a second base of a toner pattern, e.g. a powder pattern, e.g. magnetic transfer by introducing the second base in the nip formed by the recording member and at least one transfer member, e.g. in combination with bias or heat at least one of the recording member or the transfer member being rotatable during the transfer with means for conditioning the transfer element, e.g. cleaning
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03G—ELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
    • G03G2215/00—Apparatus for electrophotographic processes
    • G03G2215/16—Transferring device, details
    • G03G2215/1604—Main transfer electrode
    • G03G2215/1614—Transfer roll
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03G—ELECTROGRAPHY; ELECTROPHOTOGRAPHY; MAGNETOGRAPHY
    • G03G2215/00—Apparatus for electrophotographic processes
    • G03G2215/16—Transferring device, details
    • G03G2215/1647—Cleaning of transfer member
    • G03G2215/1657—Cleaning of transfer member of transfer drum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
ZA911553A 1990-03-02 1991-03-04 Tri-and tetra-substituted guanidines and their use as excitatory amino acid and antagonists ZA911553B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48703690A 1990-03-02 1990-03-02

Publications (1)

Publication Number Publication Date
ZA911553B true ZA911553B (en) 1991-12-24

Family

ID=23934143

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA911553A ZA911553B (en) 1990-03-02 1991-03-04 Tri-and tetra-substituted guanidines and their use as excitatory amino acid and antagonists

Country Status (15)

Country Link
US (1) US6251948B1 (pt)
EP (1) EP0517852B1 (pt)
JP (2) JP3298875B2 (pt)
KR (1) KR100353486B1 (pt)
AT (1) ATE220320T1 (pt)
AU (1) AU655176B2 (pt)
CA (1) CA2076664C (pt)
DE (1) DE69133065T2 (pt)
DK (1) DK0517852T3 (pt)
ES (1) ES2181668T3 (pt)
IE (1) IE910719A1 (pt)
PT (1) PT96930B (pt)
SG (1) SG73414A1 (pt)
WO (1) WO1991012797A1 (pt)
ZA (1) ZA911553B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
DE69230220T2 (de) * 1991-02-08 2000-06-21 Cambridge Neuroscience Res Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung
US5847006A (en) * 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
US5298657A (en) * 1992-03-20 1994-03-29 Cambridge Neuroscience Inc. Preparation of substituted guanidines
DE69418601T2 (de) * 1993-03-23 1999-09-30 Astra Ab Guanidinderivate mit therapeutischer wirkung
KR20030097618A (ko) * 1993-05-27 2003-12-31 캠브리지 뉴로사이언스, 인코포레이티드 치료용 치환 구아니딘류
JPH09505591A (ja) * 1993-11-23 1997-06-03 ケンブリッジ・ニューロサイエンス・インコーポレーテッド 治療用置換グアニジン類
KR100423272B1 (ko) * 1994-02-03 2004-09-01 캠브리지 뉴로사이언스, 인코포레이티드 신경전달물질의방출을조절하는화합물,이의약학적으로허용가능한염및이를포함하는약학조성물
US6787569B1 (en) 1994-02-03 2004-09-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
US6143791A (en) * 1994-02-03 2000-11-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
US7351743B1 (en) 1994-02-03 2008-04-01 Wyeth Therapeutic guanidines
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6756389B2 (en) * 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
HUP0001062A3 (en) 1996-09-27 2001-09-28 Guilford Pharmaceuticals Inc B Pharmaceutical compositions of phosphinic acid derivatives having naaladase inhibitor acivity
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
US6678548B1 (en) 2000-10-20 2004-01-13 The Trustees Of The University Of Pennsylvania Unified probabilistic framework for predicting and detecting seizure onsets in the brain and multitherapeutic device
EP1436258A4 (en) * 2001-03-08 2005-03-23 Univ Emory ANTAGONISTS OF THE NMDA RECEPTOR DEPENDENT OF PH
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
WO2007009462A2 (en) * 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
WO2009000038A1 (en) * 2007-06-28 2008-12-31 Cnsbio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
EP2170334B1 (en) * 2007-06-29 2021-03-17 Emory University Nmda receptor antagonists for neuroprotection
EP2254420A4 (en) 2008-02-20 2012-02-15 Targia Pharmaceuticals CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
AU2009296457A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
NL2006875C2 (en) 2011-05-31 2012-12-03 Vereniging Voor Christelijk Hoger Onderwijs N,n-substituted guanidine compound.
ES2843724T3 (es) 2015-11-30 2021-07-20 Inst Nat Sante Rech Med Antagonistas de NMDAR para el tratamiento de la angiogénesis tumoral

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1677235A (en) 1928-07-17 Balph v
US2145214A (en) 1939-01-24 Parasiticide
US1730388A (en) 1929-10-08 Winfield scott
US1422506A (en) 1921-07-02 1922-07-11 Dovan Chemical Corp Process of making diphenylguanidine
US1642180A (en) 1922-11-27 1927-09-13 Du Pont Di-para-xylylguanidine
US1597233A (en) 1923-02-27 1926-08-24 Albert C Burrage Vulcanization of rubber
GB223410A (en) 1923-11-01 1924-10-23 British Dyestuffs Corp Ltd Improvements in the manufacture of diarylguanidines
GB224376A (en) * 1923-11-01 1924-11-13 British Dyestuffs Corp Ltd Improvements in the manufacture of triarylguanidines
GB258203A (en) 1925-09-23 1926-09-16 Silesia Ver Chemischer Fabrike An improved process for the production of symmetrical di-arylguanidines
US1672431A (en) 1925-11-30 1928-06-05 Firm Chem Fab Auf Actien Vorma Symmetrical diarylized guanidine compounds
US1795398A (en) 1925-12-21 1931-03-10 Huguenin Albert Elevator for boats with constant draft
US1850682A (en) 1927-01-10 1932-03-22 Ig Farbenindustrie Ag Substituted guanidines
DE514248C (de) * 1927-09-13 1930-12-10 Schering Kahlbaum Akt Ges Verfahren zur Darstellung substituierter Guanidine
US1756315A (en) * 1927-11-28 1930-04-29 Rubber Service Lab Co Rubber vulcanization process
US1915922A (en) 1931-03-02 1933-06-27 American Cyanamid Co Mothproofing
GB478525A (en) 1936-02-13 1938-01-20 Georg Knoth Process for the preparation of diphenylguanidine
US2254009A (en) 1940-04-24 1941-08-26 American Cyanamid Co Symmetrical di-2-octyl-guanidine
US2274476A (en) 1940-08-23 1942-02-24 American Cyanamid Co Insecticide and moth larvae repellent
US2362915A (en) 1940-12-24 1944-11-14 Courtaulds Ltd Process for improving the fastness to washing of dyed cellulosic textile materials
US2289541A (en) * 1941-01-18 1942-07-14 American Cyanamid Co Insecticide
US2704710A (en) * 1950-04-18 1955-03-22 Gen Aniline & Film Corp Precipitation of azo dyes in silver halide emulsions by means of guanidine and biguanide compounds containing long alkyl chains
US2633474A (en) 1951-07-21 1953-03-31 Monsanto Chemicals 1, 3-bis (o-ethylphenyl) guanidine
US3117994A (en) * 1959-12-03 1964-01-14 Monsanto Canada Ltd Nu, nu', nu'-trisubstituted guanidines
CA940537A (en) * 1959-12-23 1974-01-22 Wellcome Foundation Limited (The) Benzyl guanidines, and a process of production
GB952194A (en) 1960-12-23 1964-03-11 Smith Kline French Lab New guanidine derivatives and processes for preparing the same
US3140231A (en) 1961-08-14 1964-07-07 Rohm & Haas T-octylguanidines as antihypertensive agents
US3159676A (en) 1962-02-07 1964-12-01 Smith Kline French Lab Naphthyl containing guanidines
US3248426A (en) 1962-03-01 1966-04-26 American Home Prod Nu-(1-naphthylmethyl)-guanidine and acid addition salt thereof
US3301755A (en) 1962-04-18 1967-01-31 Ciba Geigy Corp Allylic guanidines
CH433246A (de) * 1962-06-25 1967-04-15 Ciba Geigy Verfahren zur Herstellung von Guanidinverbindungen
US3320229A (en) 1963-08-26 1967-05-16 Stauffer Chemical Co Complexes of guanidines with completely halogenated acetones
US3479437A (en) * 1963-08-26 1969-11-18 Stauffer Chemical Co Guanidine complexes as fungicides
GB1110947A (en) 1963-12-13 1968-04-24 Evans Medical Ltd Guanidines
US3228975A (en) 1964-04-10 1966-01-11 American Cyanamid Co Akyl-substituted cyclohexyl guanidines and biguanides
NL125066C (pt) 1964-07-31
US3391189A (en) * 1966-01-13 1968-07-02 Ciba Geigy Corp Nu-allyl-guanidines and salts thereof
US3639477A (en) 1968-06-17 1972-02-01 Parke Davis & Co Novel propoxyguanidine compounds and means of producing the same
US3803324A (en) 1968-07-09 1974-04-09 Boehringer Mannheim Gmbh Amino-guanidine derivatives useful for regulating blood pressure
GB1208252A (en) * 1969-01-01 1970-10-14 American Cyanamid Co Use of alkylguanidine salts as viricides
AU1592270A (en) 1969-06-17 1971-12-09 Imperial Chemical Industries Limited Antiviral processes and compositions
US3547951A (en) 1969-06-17 1970-12-15 Waldo R Hardie 1,3-dioxolan-4-yl-alkyl guanidines
US3949089A (en) 1969-06-23 1976-04-06 Burroughs Wellcome Co. Substituted guanidine compounds as antifibrillatory agents
US4060640A (en) 1970-04-29 1977-11-29 Shell Oil Company Therapeutic agents
US3968243A (en) 1970-06-05 1976-07-06 Burroughs Wellcome Co. Substituted guanidine compounds in the treating of arrythmias
NL7011683A (pt) 1970-08-07 1972-02-09
US3908013A (en) 1970-09-17 1975-09-23 Armour Pharma Pharmaceutical aromatic guanidine compositions and methods of using same
US3681459A (en) 1970-10-01 1972-08-01 Armour Pharma Guanidine compounds and use of same
US3769427A (en) 1970-10-01 1973-10-30 Armour Pharma Pharmaceutical compositions and methods of using same
US3976787A (en) 1970-11-10 1976-08-24 Armour Pharmaceutical Company Pharmaceutical guanidine preparations and methods of using same
US3784643A (en) 1970-12-11 1974-01-08 Colgate Palmolive Co Aryloxyalkylguanidines
DE2133056C3 (de) * 1971-07-02 1980-10-23 Vsesojuznyj Nautschno-Issledovatelskij Institut Chimitscheskich Sredstv Zaschtschity Rastenij, Moskau Verwendung von NJS-di-alkyl-N'arylsubstituierten Guanidinen zur Bekämpfung von Mehltaupilzen und Grauschimmel der Pflanzen
US3795533A (en) 1971-11-24 1974-03-05 Research Corp Preservation and strengthening of porous solids
US3976643A (en) 1973-07-13 1976-08-24 William H. Rorer, Inc. Guanidines
NL7315350A (nl) 1973-11-09 1975-05-13 Akzo Nv Nieuwe aminoguanidine verbindingen.
US4007181A (en) * 1974-02-11 1977-02-08 The Upjohn Company Adamantyl containing guanidines
US4052455A (en) 1974-04-08 1977-10-04 Mead Johnson & Company Styrylamidines
US4014934A (en) 1974-04-15 1977-03-29 Armour Pharmaceutical Company Substituted 4'-hydroxyphenyl guanidines and methods of using the same
US4109014A (en) 1974-10-29 1978-08-22 Armour Pharmaceutical Company Pharmaceutical, compositions containing substituted 4'-hydroxyphenyl guanidines and methods of using same
US4130663A (en) 1975-08-04 1978-12-19 Mead Johnson & Company Styrylamidines
US4169154A (en) 1976-04-15 1979-09-25 Hoffmann-La Roche Inc. Method of treating depression with thiourea derivatives
US4051256A (en) 1976-09-19 1977-09-27 Imperial Chemical Industries Limited Guanidine derivatives
US4101659A (en) 1977-08-29 1978-07-18 Mcneil Laboratories, Incorporated Benzhydryl guanidines
US4172204A (en) 1977-10-07 1979-10-23 Syntex (U.S.A.) Inc. Method for preparing 4,5-dihydro-2-alkoxycarbonylamino-5-carbocyclic aryl imidazoles and intermediates thereof
GR73576B (pt) 1980-03-01 1984-03-20 Wyeth John & Brother Ltd
DE3108564A1 (de) * 1981-03-06 1982-11-18 Bayer Ag, 5090 Leverkusen N-tert-butyl-phenyl-n'-cyclohexyl-quanidine, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide
US4393077A (en) * 1981-07-02 1983-07-12 William H. Rorer, Inc. 1-Methylene-1-phenylguanidine compounds
FR2509724B1 (fr) * 1981-07-15 1985-10-25 Centre Nat Rech Scient Nouvelles guanidines a fort encombrement sterique et procedes pour leur preparation
US4742054A (en) * 1982-11-23 1988-05-03 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
JPS60231755A (ja) * 1984-04-02 1985-11-18 Mitsubishi Rayon Co Ltd エポキシ樹脂用添加剤
US4663263A (en) 1984-10-19 1987-05-05 Canon Kabushiki Kaisha Toner, charge-imparting material and composition containing substituted guanidine compound for electrophotography
DE3501383A1 (de) 1985-01-17 1986-07-17 Akzo Gmbh, 5600 Wuppertal Verfahren zur herstellung von n,n'-disubstituierten guanidinen
EP0259371B1 (en) * 1986-01-28 1992-05-13 JOHN WYETH & BROTHER LIMITED Preparation of 3-dimethylamino-7-methyl-1,2,4-benzotriazine-1-oxide and azapropazone
US5312840A (en) 1986-07-10 1994-05-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education Substituted guanidines having high binding to the sigma receptor and the use thereof
US5093525A (en) * 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4709094A (en) * 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use
US5190976A (en) 1986-07-10 1993-03-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5385946A (en) 1986-07-10 1995-01-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Method for treating hypertension with disubstituted granidine compounds
US4906779A (en) * 1986-07-10 1990-03-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
JPS63215034A (ja) * 1987-03-04 1988-09-07 エルナ−株式会社 固体電解コンデンサ
US4837218A (en) 1987-10-23 1989-06-06 Washington University Alkylated bicycloalkaneamines for treatment of neurotoxic injury
ES2057568T3 (es) 1989-05-02 1994-10-16 State Of Oregon By & Through O Metodos para tratar la ansiedad con ligandos de receptores sigma.
US5336689A (en) 1990-03-02 1994-08-09 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5574070A (en) * 1990-05-25 1996-11-12 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Substituted guanidines having high binding to the sigma receptor and the use thereof
JPH06501002A (ja) 1990-08-30 1994-01-27 オレゴン州 シグマ受容体に対して高い結合性を有する置換アミジン類およびその使用
DE69230220T2 (de) * 1991-02-08 2000-06-21 Cambridge Neuroscience Res Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung
US5298657A (en) 1992-03-20 1994-03-29 Cambridge Neuroscience Inc. Preparation of substituted guanidines

Also Published As

Publication number Publication date
EP0517852B1 (en) 2002-07-10
ATE220320T1 (de) 2002-07-15
PT96930A (pt) 1991-11-29
EP0517852A1 (en) 1992-12-16
KR100353486B1 (ko) 2003-01-06
JP2002020361A (ja) 2002-01-23
DE69133065D1 (de) 2002-08-14
JP3298875B2 (ja) 2002-07-08
CA2076664A1 (en) 1991-09-03
EP0517852A4 (pt) 1994-03-02
AU655176B2 (en) 1994-12-08
US6251948B1 (en) 2001-06-26
ES2181668T3 (es) 2003-03-01
JP3341000B2 (ja) 2002-11-05
CA2076664C (en) 2004-01-13
PT96930B (pt) 1998-06-30
AU7579691A (en) 1991-09-18
SG73414A1 (en) 2000-06-20
IE910719A1 (en) 1991-09-11
DE69133065T2 (de) 2003-02-27
JPH05507062A (ja) 1993-10-14
DK0517852T3 (da) 2002-10-07
WO1991012797A1 (en) 1991-09-05

Similar Documents

Publication Publication Date Title
SG73414A1 (en) Tri-and tetra-substituted guanidines and their use as excitatory amino acid antagonists
HUP9904525A2 (hu) S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények
CA2050284A1 (en) PCP Receptor Ligands and the Use Thereof
EP0703785B8 (en) Methods for treating muscle diseases and disorders
DE69223965T2 (de) Anticonvulsives aminosäurederivat
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
ATE555780T1 (de) Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen
MX9708977A (es) Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas.
DK0812190T3 (da) R-enantiomer af N-propargyl-1-aminoindan til behandling af forskellige sygdomme og mesylat, esulat og sulfat deraf
UA42885C2 (uk) 4-аміно-2-(4-метилпіперазин-1-іл)-5-(2,3,5-трихлорфеніл)піримідин, що має інгібуючу активність вивільнення глутамату, спосіб його одержання та фармацевтична композиція на його основі
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
MY131442A (en) Excitatory amino acid receptor antagonists
TR199902291T2 (xx) �kame edilmi� 4-Arilmetilen-2-imino-2, 3-dihidrotiazoller
BR0311558A (pt) composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
TR200002570T2 (tr) Glisin naklini önleyiciler
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
AU6269594A (en) Methods for treating neurodegenerative diseases and disorders using n-(2,6-disubstituted aromatic)-n'-pyridinyl ureas and other anticonvulsant compounds
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
EP1016407A4 (en) REMEDY FOR NEURAL DEGENERATION
TW197423B (pt)
NZ332829A (en) Use of a polypeptide corresponding to a serine threonine kinase receptor, ALK-7 for neurological diseases
TR199901304A2 (xx) Spiro $Piperidin-4,1'-Pirrolo $3,4-c]Pirrol ]
GR3015132T3 (en) Novel ureas and thioureas, preparation thereof and application in therapy.
CA2257234A1 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
TH20134EX (th) ผลการป้องกันระบบประสาทแบบปฐมภูมิและทุติยภูมิของฟลูเพอร์ทีน ในโรคการเสื่อมของระบบประสาท